A Network Pharmacology and Molecular Docking Strategy to Explore Potential Targets and Mechanisms Underlying the Effect of Curcumin on Osteonecrosis of the Femoral Head in Systemic Lupus Erythematosus

BioMed Research International, Год журнала: 2021, Номер 2021, С. 1 - 14

Опубликована: Сен. 13, 2021

Systemic lupus erythematosus (SLE) is a refractory immune disease, which often complicated with osteonecrosis of the femoral head (ONFH). Curcumin, most active ingredient Curcuma longa variety biological activities, has wide effects on body system. The study aimed at exploring potential therapeutic targets underlying effect curcumin SLE-ONFH by utilizing network pharmacology approach and molecular docking strategy.Curcumin its drug were identified using analysis. First, Swiss target prediction, GeneCards, OMIM databases mined for information relevant to prediction SLE-ONFH-related targets. Second, gene, shared curcumin-SLE-ONFH gene networks created in Cytoscape software followed collecting candidate each component R software. Third, enriched pathways examined Gene Ontology (GO) Kyoto Encyclopedia Genes Genomes (KEGG) pathway enrichment Eventually, gene-pathway was constructed visualized software; key central verified checked literature review.201 170 related involved subjected analysis, 36 intersection indicated treatment SLE-ONFH. Additionally, getting more comprehensive accurate genes, determined be analyzed topology 285 genes obtained finally. top 20 processes, cellular components, functions identified, when corrected P value ≤ 0.05. signaling KEGG according Bonferroni Molecular showed that three (TP53, IL6, VEGFA) have good binding force curcumin; combined review, some other such as TNF, CCND1, CASP3, MMP9 also identified.The present explored against SLE-ONFH, could provide better understanding terms regulating cell cycle, angiogenesis, immunosuppression, inflammation, bone destruction.

Язык: Английский

---

Systemic consequences of abnormal cholesterol handling: Interdependent pathways of inflammation and dyslipidemia

Frontiers in Immunology, Год журнала: 2022, Номер 13

Опубликована: Авг. 26, 2022

Metabolic conditions such as obesity and associated comorbidities are increasing in prevalence worldwide. In chronically inflamed pathologies, metabolic linked to early onset cardiovascular disease, which remains the leading cause of death despite decades research. recent years, studies focused on interdependent pathways connecting metabolism immune response have highlighted that dysregulated cholesterol trafficking instigates an overactive, systemic inflammatory response, thereby perpetuating development disease. this review, we will discuss overlapping with innate immunity present evidence accumulation bone marrow may drive inflammation pathologies. Lastly, review current therapeutic strategies target both transport, how biologic therapy restores lipoprotein function mitigates response.

Язык: Английский

---

Systemic lupus erythematosus therapeutic strategy: From immunotherapy to gut microbiota modulation

Journal of Biomedical Research, Год журнала: 2024, Номер 38(6), С. 531 - 531

Опубликована: Янв. 1, 2024

Systemic lupus erythematosus (SLE) is characterized by a systemic dysfunction of the innate and adaptive immune systems, leading to an attack on healthy tissues body. During development SLE, pathogenic features, such as formation autoantibodies self-nuclear antigens, caused tissue damage including necrosis fibrosis, with increased expression type Ⅰ interferon (IFN) regulated genes. Treatment immunosuppressants glucocorticoids, which are used standard therapy, not effective enough causes side effects. As alternative, more immunotherapies have been developed, monoclonal bispecific antibodies that target B cells, T co-stimulatory molecules, cytokines or their receptors, signaling molecules. Encouraging results observed in clinical trials some these therapies. Furthermore, chimeric antigen receptor cells (CAR-T) therapy has emerged most effective, safe, promising treatment option for demonstrated successful pilot studies. Additionally, emerging evidence suggests gut microbiota dysbiosis may play significant role severity use methods normalize microbiota, particularly fecal transplantation (FMT), opens up new opportunities SLE.

Язык: Английский

---

The reduced frequency of CD39+CD73+ B cell subsets in SLE patients is correlated with disease activity

International Immunopharmacology, Год журнала: 2024, Номер 140, С. 112743 - 112743

Опубликована: Авг. 1, 2024

Язык: Английский

---

CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Дек. 19, 2024

Systemic lupus erythematosus (SLE) and nephritis (LN) are debilitating autoimmune disorders characterized by pathological autoantibodies production immune dysfunction, causing chronic inflammation multi-organ damage. Despite current treatments with antimalarial drugs, glucocorticoids, immunosuppressants, monoclonal antibodies, a definitive cure remains elusive, highlighting an urgent need for novel therapeutic strategies. Recent studies indicate that chimeric antigen receptor T-cell (CAR-T) therapy has shown promising results in treating B-cell malignancies may offer significant breakthrough non-malignant conditions like SLE. In this paper, we aim to provide in-depth analysis of the advancements CAR-T SLE, focusing on its potential revolutionize treatment complex disease. We explore fundamental mechanisms cell action, rationale application immunological underpinnings also summarize clinical data safety efficacy anti-CD19 anti-B maturation (BCMA) cells targeting B-cells discuss implications these findings improve outcomes severe or refractory SLE cases. The integration into paradigm presents new horizon autoimmunity research practice. This review underscores continued exploration optimization strategies address unmet needs patients.

Язык: Английский

---